AveXis, Inc. (NASDAQ:AVXS) has been given a consensus rating of “Buy” by the twelve research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $105.88.

AVXS has been the topic of several analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $95.00 price target on shares of AveXis in a report on Friday, June 16th. Jefferies Group LLC reaffirmed a “buy” rating on shares of AveXis in a report on Wednesday, June 28th. Morgan Stanley reaffirmed an “overweight” rating and set a $118.00 price target on shares of AveXis in a report on Wednesday. Citigroup Inc. set a $100.00 price target on shares of AveXis and gave the company a “buy” rating in a report on Thursday, June 15th. Finally, Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th.

AveXis (NASDAQ:AVXS) traded down 1.94% during mid-day trading on Friday, reaching $89.88. 505,560 shares of the company’s stock traded hands. The company’s market cap is $2.50 billion. AveXis has a 12-month low of $31.55 and a 12-month high of $97.77. The stock has a 50 day moving average of $85.30 and a 200 day moving average of $73.61.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($0.97) by $1.10. During the same quarter last year, the firm earned ($0.68) EPS. On average, equities research analysts predict that AveXis will post ($4.36) earnings per share for the current fiscal year.

In other news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $91.52, for a total value of $162,905.60. Following the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $162,905.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 5,340 shares of company stock worth $434,872 in the last three months. Insiders own 18.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in AveXis by 3,055.6% in the first quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after buying an additional 1,654,248 shares during the period. Alliancebernstein L.P. increased its position in AveXis by 4,448.8% in the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after buying an additional 552,546 shares during the period. FMR LLC increased its position in AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after buying an additional 544,475 shares during the period. Vanguard Group Inc. increased its position in AveXis by 31.8% in the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the period. Finally, Marshall Wace North America L.P. increased its position in AveXis by 813.3% in the second quarter. Marshall Wace North America L.P. now owns 303,084 shares of the company’s stock valued at $24,853,000 after buying an additional 269,900 shares during the period. 90.68% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “AveXis, Inc. (NASDAQ:AVXS) Given Consensus Recommendation of “Buy” by Analysts” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/avexis-inc-nasdaqavxs-given-consensus-recommendation-of-buy-by-analysts.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.